BAX vs VTRS vs SKYA Stock Comparison

Baxter International, Viatris and SkyAI Prices as of Nov 3, 2026 Peers: Industry group
1 more company in this comparison (STVN) Create a free account to keep reading and compare up to 10 companies.
VTRS Viatris Inc
$18.92 +7.5% 1M +79.7% 1Y
Market cap
$22.32B
P/E
–
Revenue (TTM)
$14.74B
Div. yield
–
Generic Drugs Healthcare
8 wins
SKYA SkyAI, Inc.
$2.95 +60.3% 1M -31.1% 1Y
Market cap
$213.04M
P/E
–
Revenue (TTM)
$174.18K
Div. yield
–
Medical Supplies Healthcare
2 wins

Head to Head

10 decided of 12

Viatris leads on 8 of the 12 questions below (Viatris 8, SkyAI 2). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionBAXVTRSSKYALeader
Larger companyMarket capitalisation $13.65B $22.32B $213.04M VTRS
Cheaper on earningsLower P/E, profitable companies only -18.9x -54.4x -0.5x –
Cheaper on forward earningsLower price / next fiscal year consensus EPS 12.9x 7.2x 0.0x SKYA
Faster revenue growthRevenue growth, trailing twelve months +5.3% +4.4% +108.0% SKYA
More profitableNet margin, trailing twelve months -6.2% -2.8% -228,220.7% VTRS
Better return on capitalReturn on invested capital -1.4% -0.2% — VTRS
Less leveragedLower net debt / EBITDA 9.0x 4.6x — VTRS
Higher dividend yieldTrailing dividend yield 0.01% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +40.0% +79.7% -31.1% VTRS
Better 5-year returnAnnualised price return, 5 years -20.1%/yr +6.7%/yr — VTRS
Less volatileAnnualised volatility, 1 year 42.7% 32.5% 105.3% VTRS
Higher overall scoreMean of the five percentile scores vs peers 43/100 66/100 27/100 VTRS

Percentile Scorecard

BAXVTRSSKYA

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisBAXVTRSSKYA
Valuation 86 #34 of 229 94 #41 of 634 4 #220 of 229
Growth 14 #191 of 221 48 #319 of 607 4 #212 of 221
Profitability 65 #73 of 209 82 #102 of 557 1 #208 of 209
Financial Health 18 #197 of 240 24 #500 of 654 95 #13 of 240
Shareholder Returns 34 #97 of 147 83 #68 of 401 34 #98 of 147
Overall 43 66 27
  • BAX ranked among 248 companies in Medical Devices and Diagnostics
  • VTRS ranked among 671 companies in Pharmaceuticals and Biotechnology
  • SKYA ranked among 248 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodBAXVTRSSKYASPY
1 month +8.5%+7.5%+60.3% -2.0%
3 months -10.1%+6.9%+126.9% -2.2%
6 months +52.2%+21.9%+55.3% +4.2%
Year to date +33.4%+52.0%+45.3% +10.6%
1 year +40.0%+79.7%-31.1% +10.4%
3 years -24.9%+104.1%-99.9% +73.6%
3 years, per year -9.1%+26.9%-90.0% +20.2%
5 years -67.4%+38.3%— +61.6%
5 years, per year -20.1%+6.7%— +10.1%
10 years -45.6%-44.6%— +261.3%
10 years, per year -5.9%-5.7%— +13.7%

Risk

MeasureBAXVTRSSKYASPY
Volatility, 1Y 42.7%32.5%105.3% 12.8%
Downside volatility, 1Y 44.1%29.7%104.8% 12.8%
Beta vs S&P 500, 1Y 1.080.712.49 1.00
Return / volatility, 1Y 0.942.45-0.30 0.81
Max drawdown, 5Y -82.3%-52.9%-100.0% -25.4%
From 52-week high -10.1%-1.5%-31.1% -3.2%
52-week high $28.35$19.20$4.28 $779.14
52-week low $15.80$10.11$0.95 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleBAXVTRSSKYA
P/E now vs peer median -18.2xmedian 28.1x -53.6xmedian 18.4x -0.5xmedian 28.1x
P/S now vs peer median 1.1xmedian 2.9x 1.5xmedian 9.0x 1,221xmedian 2.9x
EV/EBITDA now vs peer median 27.0xmedian 18.0x 12.6xmedian 16.0x -0.5xmedian 18.0x
P/FCF now vs peer median 11.4xmedian 24.8x 11.1xmedian 21.8x -1.1xmedian 24.8x
P/B now vs peer median 2.0xmedian 2.3x 1.5xmedian 2.1x 1.4xmedian 2.3x
PEG now vs peer median 0.58median 0.95 1.75median 0.37 0.01median 0.95

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsBAXVTRSSKYA
Revenue $11.61B $14.74B $174.18K
Gross profit $3.49B $5.13B $324.68K
Operating income -$221.00M -$87.30M -$374.36M
Net income -$723.00M -$410.70M -$397.51M
Free cash flow $1.16B $1.95B -$201.93M
R&D $519.00M $1.02B $475.55K
EPS (diluted) $-1.39 $-0.35 $-5.51
Cash & equivalents $1.98B $886.50M $12.07M
Total debt $8.60B $13.35B –
Shares (diluted) 520.00M 1.16B 72.09M
Enterprise value $5.53B $17.34B $167.74M

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricBAXVTRSSKYA
P/E -18.2x -53.6x -0.5x
P/FCF 11.4x 11.1x -1.1x
P/Operating cash flow 7.9x 9.3x -14.8x
P/S 1.1x 1.5x 1,221x
P/B 2.0x 1.5x 1.4x
P/Tangible book 5.1x 37.2x 16.4x
EV/EBITDA 27.0x 12.6x -0.5x
EV/EBIT -89.6x -391.7x -0.5x
EV/Revenue 1.7x 2.3x 1,152x
EV/FCF 17.1x 17.5x -1.0x
EV/Operating cash flow 11.9x 14.7x -13.9x
PEG (3Y EPS CAGR) 0.58 1.75 0.01

Growth

14 metrics
MetricBAXVTRSSKYA
Revenue growth (1Y) 5.3% 4.4% 108.0%
Revenue CAGR (3Y) 0.7% -1.9% 19.4%
Gross profit growth (1Y) -7.1% -0.7% –
Gross profit CAGR (3Y) -7.7% -6.0% –
Operating income growth (1Y) -136.3% 96.6% -8,055%
Operating income CAGR (3Y) 4.2% -27.6% -240.7%
Net income growth (1Y) -112.0% 88.2% -54,854%
Net income CAGR (3Y) -31.6% -30.5% -268.2%
EPS growth (1Y) -109.6% 88.1% -658.6%
EPS CAGR (3Y) -31.5% -30.6% -100.6%
Operating cash flow growth (1Y) 97.4% 12.9% -356.8%
Operating cash flow CAGR (3Y) 0.6% -3.0% -24.4%
Free cash flow growth (1Y) 243.5% 11.6% -6,031%
Free cash flow CAGR (3Y) -5.0% -3.6% -196.9%

Profitability

14 metrics
MetricBAXVTRSSKYA
Gross margin 30.1% 34.8% 186.4%
EBITDA margin 6.3% 18.4% -214,892%
Operating margin -1.9% -0.6% -214,931%
Pretax margin -1.6% -4.5% -221,236%
Net margin -6.2% -2.8% -228,221%
FCF margin 10.0% 13.3% -115,934%
Operating cash flow margin 14.3% 15.8% -8,259%
Return on equity -11.4% -2.8% -280.7%
Return on assets -3.7% -1.1% -276.3%
Return on invested capital -1.4% -0.2% –
Return on capital employed -1.4% -0.3% -223.1%
Asset turnover 0.6x 0.4x 0.0x
Cash conversion (OCF / net income) -2.3x -5.7x 0.0x
Stock comp / revenue 0.9% 1.2% 52,451%

Financial Health

11 metrics
MetricBAXVTRSSKYA
Debt / assets 44.3% 38.1% –
Debt / equity 1.3x 0.9x –
Net debt / EBITDA 9.0x 4.6x –
Debt / FCF 7.4x 6.8x –
Liabilities / assets 66.5% 59.3% 1.9%
Equity / assets 33.5% 40.7% 98.1%
Interest coverage – -0.2x –
Current ratio 1.8x 1.6x 5.3x
Quick ratio 1.0x 0.7x 4.4x
Cash ratio 0.5x 0.1x 4.2x
Altman Z-score 2.38 1.15 30.23

Shareholder Returns

7 metrics
MetricBAXVTRSSKYA
Dividend yield 0.2% 2.5% –
Net buyback yield -0.2% 1.4% -0.6%
Shareholder yield 0.0% 3.9% -0.6%
Payout ratio (earnings) -14.1% – –
Payout ratio (FCF) 8.8% – –
Dividend growth (1Y) -75.0% – –
Dividend CAGR (3Y) -44.1% – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusBAXVTRSSKYA
Forward P/E 12.9xFY2026 7.2xFY2026 0.0xFY2026
EPS, next fiscal year $1.98FY2026 $2.62FY2026 $2,362.06FY2026
EPS growth, next FY -10.4%FY2026 +11.5%FY2026 –
EPS growth, the year after -3.5% -1.5% –
Revenue, next fiscal year $11.05BFY2026 $15.31BFY2026 $70.01MFY2026
Revenue growth, next FY -1.7%FY2026 +7.0%FY2026 +34,200.1%FY2026
Revenue growth, the year after +11.7% -4.8% +17.5%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersBAXVTRSSKYA
Held by institutions 100.0% 89.9% –
Institutions holding 692 1,032 –
Change in shares held, QoQ +5.2% +5.6% –
Institutions buying 359 490 –
Institutions selling 194 318 –
Buyers to sellers 1.85 1.54 –

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

BAXVTRSSKYA
BAX 1.00 0.31 0.08
VTRS 0.31 1.00 0.03
SKYA 0.08 0.03 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, BAX, VTRS and SKYA?

Viatris (VTRS) is the largest by market capitalisation: Baxter International (BAX) $13.65B, Viatris (VTRS) $22.32B, SkyAI (SKYA) $213.04M.

Which company is growing faster?

SkyAI (SKYA) grew revenue fastest over the trailing twelve months: Baxter International (BAX) +5.3%, Viatris (VTRS) +4.4%, SkyAI (SKYA) +108.0%.

Which company is more profitable?

Viatris (VTRS) has the highest net margin (Baxter International (BAX) -6.2%, Viatris (VTRS) -2.8%, SkyAI (SKYA) -228,220.7%). On return on invested capital, Viatris (VTRS) leads (Baxter International (BAX) -1.4%, Viatris (VTRS) -0.2%).

Which stock has performed better?

Over the past year Viatris (VTRS) returned the most: Baxter International (BAX) +40.0%, Viatris (VTRS) +79.7%, SkyAI (SKYA) -31.1%. Over five years, Viatris (VTRS) compounded fastest (Baxter International (BAX) -20.1%/yr, Viatris (VTRS) +6.7%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: Baxter International (BAX) 0.01%, Viatris (VTRS) 0.00%, SkyAI (SKYA) 0.00%. Viatris (VTRS) and SkyAI (SKYA) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Viatris (VTRS) has been the steadiest (Baxter International (BAX) 42.7%, Viatris (VTRS) 32.5%, SkyAI (SKYA) 105.3%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, BAX, VTRS and SKYA?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Viatris (VTRS) leads on 8. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.